
About Artiva:
We are a clinical-stage biotechnology company focused on developing natural killer (NK) cell-based therapies. Our mission is to develop effective, safe, and accessible cell therapies for patients with devastating autoimmune diseases. We aim to develop therapies that patients and physicians can utilize in a community setting. Our lead product candidate, AlloNK®, is a non-genetically modified, cryopreserved NK cell therapy being evaluated in combination with B-cell targeted monoclonal antibodies (mAbs). We believe the compelling cell-killing properties of NK cells, when combined with mAbs for targeting, create an opportunity to generate potentially transformative therapies. For more information, visit www.artivabio.com
Join Artiva Biotherapeutics in San Diego and work directly on the manufacturing floor to produce our innovative, off-the-shelf cell therapies in a state-of-the-art cGMP facility. Apply your expertise across cell culture, aseptic processing, harvest and fill-finish, playing a direct role in advancing therapies for patients with autoimmune diseases. This is a contract-only position.
Summary
The successful candidate will play a key role in the manufacturing of cell therapies internally at Artiva. He/ she will execute hands-on manufacturing processes to deliver new revolutionary therapeutics. The ideal candidate will demonstrate in-depth knowledge of cGMP compliance, strong hands-on laboratory skills and work in a high-performing team of manufacturing associates.
Working Conditions and Physical Requirements
NO AGENCIES PLEASE
In addition to a great culture, we offer:
If all this speaks to you, come join us on our journey!
Base Salary: $36-$50 per hour. Exact compensation may vary based on level, skills, and experience.

Artiva Biotherapeutics is an immunotherapy company with the ability to produce off-the-shelf, allogeneic NK cell therapies at a massive scale. Our mission is to develop effective, safe and accessible cell therapies for patients with devastating autoimmune diseases and cancers. Our lead program, AlloNK®, is an allogeneic, non-genetically modified NK cell therapy candidate designed to enhance the activity of monoclonal antibodies or NK cell engagers. AlloNK is currently in clinical trials in combination with rituximab for treatment of systemic lupus erythematosus (SLE) in patients with active lupus nephritis and for treatment of Non-Hodgkin Lymphoma, as well as in combination with Affimed’s innate cell engager AFM13 for the treatment of patients with relapsed/refractory CD30-positive lymphomas.